We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc


28 Jan 2019 - 01 Feb 2019
02 Feb 2019 - 07 Feb 2019
16 Feb 2019 - 21 Feb 2019

Optical Scintillation Detector Monitors Radiation Treatments

By Medimaging International staff writers
Posted on 15 Nov 2017
Print article
Image: An optical system measures and validates radiation doses (Photo courtesy of RadiaDyne).
Image: An optical system measures and validates radiation doses (Photo courtesy of RadiaDyne).
A new system provides diagnostic pinpoint accuracy measurement of the radiation treatment plan by verifying the dose delivered is consistent with the prescribed dose.

The RadiaDyne (Houston, TX, USA) OARtrac system is a real-time in vivo dosimetry device system that uses disposable scintillating detectors during stereotactic body radiotherapy (SBRT) and intensity-modulated radiation therapy (IMRT) for prostate cancer treatment or brachytherapy. The system is based on plastic scintillation detector (PSD) probes connected to a duplex fiber-optical cable that transmits the PSD signals to a charge coupled device (CCD) camera that measures the scintillator output signal.

The optical measurement is converted to an electrical signal and displayed on a digital readout located in the control room of the linear accelerator treatment machine. Based on the continuous review of the accumulative dose data provided by the system, radiation oncologists can adjust subsequent treatment if and when required, thus allowing for a true adaptive radiation therapy protocol. The PSD sensor cable can be used up to five times on the same patient.

“Radiation oncologists can now monitor multiple radiation delivery modalities within the same treatment center, as well as reduce overall treatment costs related to routine patient dose monitoring,” said John Isham, founder of RadiaDyne.

Organs at risk (OAR) are defined as normal tissues whose radiation sensitivity may significantly influence treatment planning and/or the prescribed radiation dose.

Related Links:

Print article


Copyright © 2000-2019 Globetech Media. All rights reserved.